Agios' Supplemental New Drug Application for Its Thalassemia Treatment Gets FDA Nod
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
Agios Pharmaceuticals Says FDA Accepted SNDA For PYRUKYND (Mitapivat) For Treatment Of Adult Patients With Non-Transfusion-Dependent And Transfusion-Dependent Alpha- Or Beta-thalassemia
Express News | Agios Pharmaceuticals Inc - Pdufa Goal Date for Pyrukynd Snda Is September 7, 2025
FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND (Mitapivat) in Adult Patients With Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $55
